HELIOS Kliniken

Treatment landscape and prognosis after treatment with trastuzumab emtansine (2020) Laakmann E, Emons J, Taran FA, Janni W, Uhrig S, Overkamp F, Kolberg HC, et al. Journal article S2k-Leitlinie: Management der Großgefäßvaskulitiden (2020) Schirmer JH, Aries PM, Balzer K, Berlit P, Bley TA, Buttgereit F, Czihal M, et al. Journal article, Review article S2k-Leitlinie (Kurzfassung): Management der Großgefäßvaskulitiden (2020) Schirmer JH, Aries PM, Balzer K, Berlit P, Bley TA, Buttgereit F, Czihal M, et al. Journal article, Review article Older age onset of systemic sclerosis - accelerated disease progression in all disease subsets (2020) Moinzadeh P, Kuhr K, Siegert E, Mueller-Ladner U, Riemekasten G, Günther C, Kötter I, et al. Journal article Brain fMRI Predicts Responses to Certolizumab Pegol in RA. an International, Multi-center, Randomized, Double-blind, Placebocontrolled Trial (PreCePRA) (2020) Rech J, Schenker H, Tascilar K, Hagen M, Kleyer A, Simon D, Mendez LV, et al. Conference contribution Use of a molecular Registry (PRAEGNANT) for Patient-Selection and Biomarker-Analysis for the SHERBOC Study (2020) Hübner H, Kurbacher C, Kuesters G, Hartkopf AD, Lux MP, Huober J, Volz B, et al. Conference contribution Progression-free survival and overall survival in patients with advanced her2-positive breast cancer treated with trastuzumab emtansine (T-dm1) after previous treatment with pertuzumab (2020) Michel LL, Hartkopf AD, Fasching P, Kolberg HC, Hadji P, Tesch H, Häberle L, et al. Journal article Age- And weight-adapted dose of prasugrel versus standard dose of ticagrelor in patients with acute coronary syndromes: Results from a randomized trial (2020) Menichelli M, Neumann FJ, Ndrepepa G, Mayer K, Woehrle J, Bernlochner I, Richardt G, et al. Journal article Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triplenegative breast cancer, TNBC) (PM(Cb)) for patients (pts) with highrisk early breast cancer (BC) (2020) Schneeweiss A, Moebus V, Tesch H, Klare P, Denkert C, Kast K, Hanusch C, et al. Conference contribution GeparX: Denosumab (Dmab) as add-on to different regimen of nab-paclitaxel (nP)-anthracycline based neoadjuvant chemotherapy (NACT) in early breast cancer (BC): Subgroup analyses by RANK expression and HR status (2020) Link T, Blohmer JU, Just M, Untch M, Stoetzer O, Fasching P, Schneeweiss A, et al. Conference contribution